文献速递消化道肿瘤放疗放疗物理与技术

不可切除胰腺癌SBRT后局部进展评估:CT与PET对比

Assessing local progression after stereotactic body radiation therapy for unresectable pancreatic adenocarcinoma: CT versus PET.
PubMed 文献 · Pract Radiat Oncol · 2016-09-07

26例有随访FDG-PET的局部进展患者中,FDG-PET检出21例(80.7%),CT检出14例(53.8%),仅9例(34.6%)两者均检出;1年和2年局部进展累积发生率CT为9.6%和16.7%,FDG-PET为11%和29.1%。结论认为FDG-PET可提高SBRT后局部进展检出率,推荐用于疗效评估。

要点

  • FDG-PET检出80.7%的局部进展,CT仅检出53.8%。
  • 仅用CT会漏诊约一半FDG-PET可检出的局部进展。
  • FDG-PET评估的2年局部进展累积发生率高于CT(29.1% vs 16.7%)。

核心结论

  • FDG-PET可提高不可切除胰腺癌SBRT后局部进展的检出率,并对报告结局有重要影响。
  • 推荐在评估SBRT疗效时获取FDG-PET以评估治疗反应,并在比较临床数据时考虑其使用。

研究设计与样本

  • 分别采用RECIST 1.1标准评估CT和PERCIST 1.0标准评估FDG-PET,独立分析局部进展。

主要发现

  • 206例中30例随访发现局部进展,其中4例未行随访FDG-PET。
  • SBRT后至局部进展的中位时间为7.5个月(范围2-25个月)。
  • 26例有随访FDG-PET的局部进展患者中,FDG-PET诊断21例(80.7%),CT诊断14例(53.8%),两者均诊断9例(34.6%)。
  • 基于竞争风险死亡,SBRT后1年和2年局部进展累积发生率CT为9.6%和16.7%,FDG-PET为11%和29.1%。

关键数值与推荐

  • CT评估局部进展采用RECIST 1.1标准。
  • FDG-PET评估局部进展采用PERCIST 1.0标准。

临床怎么用

  • 在评估不可切除胰腺癌SBRT疗效时,建议获取FDG-PET以辅助局部进展评估。
  • 在比较临床数据或报告结局时,应考虑是否使用FDG-PET进行局部进展评估。

局限性

  • 本研究为单中心回顾性分析。
  • 30例局部进展患者中4例未行随访FDG-PET,可能影响检出率比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Evaluation of local tumor progression (LP) has typically been defined by contrast-enhanced computed tomography (CT) imaging after stereotactic body radiation therapy (SBRT) for locally advanced pancreatic cancer (PDAC). The purpose of this study is to determine the benefit of adding 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) imaging to CT for LP assessment of PDAC after SBRT. METHODS AND MATERIALS: We retrospectively reviewed pretreatment, follow-up images, and outcomes of all patients treated with definitive SBRT for unresectable PDAC between December 2002 and December 2015 at our institution. For each patient, we independently analyzed LP both by CT and by FDG-PET criteria, using the Response Evaluation Criteria In Solid Tumors version 1.1 and the FDG-PET Response Evaluation Criteria In Solid Tumors version 1.0, respectively. RESULTS: Among 206 patients treated with definitive SBRT for unresectable PDAC, we identified 30 with LP on follow-up. Four did not undergo follow-up FDG-PET. Median time to LP after SBRT was 7.5 months (range, 2-25 months). Of the 26 patients with LP who had follow-up FDG-PET, 21 were diagnosed by FDG-PET (80.7%), 14 by CT (53.8%), and 9 by both FDG-PET and CT (34.6%). Use of CT alone revealed only 53.8% of cases of LP detected when FDG-PET and CT were combined. The cumulative incidence of LP, based on competing risk of death, at 1 and 2 years after SBRT was 9.6% and 16.7% by CT and 11% and 29.1% by FDG-PET, respectively. CONCLUSION: FDG-PET increases the chance of detecting LP of unresectable PDAC after SBRT and can have an important impact on reported outcomes. We recommend obtaining FDG-PET to assess treatment response when evaluating efficacy of SBRT and taking its use into account when comparing clinical data.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Toesca DAS, Pollom EL, Poullos PD, et al. Assessing local progression after stereotactic body radiation therapy for unresectable pancreatic adenocarcinoma: CT versus PET. Pract Radiat Oncol. 2016. PMID: 28274396. doi:10.1016/j.prro.2016.09.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。